Clinical

Clinical  ·  Type 1 Diabetes
REMD Biotherapeutics’ Volagidemab T1D Phase 2 positive top-line results reported

Type 1 Diabetes – January 2021 Type 1 Diabetes – January 2021 REMD Biotherapeutics announced completion of enrollment and top-line results from Phase 2 trial of Volagidemab in patients with Type 1 Diabetes 07 Jan 2021 Volagidemab/ REMD-477 (Human IgG2 […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Type 1 Diabetes
T-cell protein a target for prevention of Type 1 Diabetes

Type 1 Diabetes – January 2021 Type 1 Diabetes – January 2021 Preclinical results in mice targeting transcriptional coregulator OCA-B/Pou2af1 and its effect on Type 1 Diabetes 09 Dec 2020 Objective: To assess if T cell-specific OCA-B deletion and pharmacologic […]

by Sandhya Ramalingam

Continue Reading